Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Novartis - Gevokizumab and IL-1 Beta (Details)

v3.21.2
Licensing and Other Arrangements - Novartis - Gevokizumab and IL-1 Beta (Details)
$ / shares in Units, $ in Thousands, € in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 24, 2017
USD ($)
item
agreement
$ / shares
shares
Aug. 24, 2017
EUR (€)
item
agreement
shares
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2020
USD ($)
Licensing and other arrangements                
Proceeds from issuance of common stock         $ 17 $ 26    
Revenue from contracts with customers     $ 550 $ 200 1,094 753    
Novartis Pharma AG [Member] | Gevokizumab License Agreement and IL-1 Target License Agreement                
Licensing and other arrangements                
Transaction price $ 40,200              
Cash payment received 25,700              
License agreement consideration received, repayment of debt 14,300              
Common stock premium $ 200              
Number of license agreements | agreement 2 2            
Number of arrangements | item 1 1            
Number of performance obligations | item 2 2            
Remaining performance obligations     0   0      
Revenue from contracts with customers     0 $ 0 0 $ 0 $ 40,200  
Contract assets     0   0     $ 0
Contract liabilities     0   0     0
Capitalized contract costs     $ 0   $ 0     $ 0
Novartis Pharma AG [Member] | Gevokizumab License Agreement                
Licensing and other arrangements                
License agreement consideration received $ 30,000              
Cash payment received 15,700              
License agreement consideration received, repayment of debt 14,300 € 12.0            
Proceeds from issuance of common stock 5,000              
Common stock premium 200              
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 438,000              
Agreement termination prior written notice period 6 months 6 months            
Novartis Pharma AG [Member] | Gevokizumab License Agreement | Common Stock [Member]                
Licensing and other arrangements                
Shares issued (in shares) | shares 539,131 539,131            
Purchase price (in dollars per share) | $ / shares $ 9.2742              
Issuance of common stock, fair value $ 4,800              
Closing stock price (in dollars per share) | $ / shares $ 8.93              
Novartis Pharma AG [Member] | IL-1 Target License Agreement [Member]                
Licensing and other arrangements                
Cash payment received $ 10,000